A new era in the treatment of cystic fibrosis: Correction of the underlying CFTR defect

The Lancet Respiratory Medicine

Volumn 1, Issue 2, 2013, Pages 158-163

  Boyle, Michael P ^a   De Boeck, Kris ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; UNCLASSIFIED DRUG; VX 661;

CELL SURFACE; CHANNEL GATING; CHLORIDE TRANSPORT; CHROMOSOME DELETION; CTFR GENE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; GENE; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HOMOZYGOSITY; HUMAN; NONSENSE MUTATION; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

AMINOPHENOLS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; OXADIAZOLES; PROTEIN BIOSYNTHESIS; QUINOLONES; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 84880044346     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(12)70057-7     Document Type: Review

References (35)

1. Boucher RC Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007, 13:231-240.
2. Gentzsch M, Dang H, Dang Y, et al. The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J Biol Chem 2010, 285:32227-32232.
3. Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:174-183.
4. Jacquot J, Tabary O, Le Rouzic P, Clement A Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol 2008, 40:1703-1715.
5. Boucher RC Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007, 261:5-16.
6. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
7. Amaral MD, Kunzelmann K Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007, 28:334-341.
8. Clunes MT, Boucher RC Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008, 8:292-299.
9. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
10. Sloane PA, Rowe SM Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med 2010, 16:591-597.
11. Clinical and Functional Translation of CFTR. Baltimore, MD, USA: US CF Foundation, Johns Hopkins University, The Hospital for Sick Children; c2011-2012 CFTR2, (accessed Nov 16, 2012). http://www.cftr2.org/.
12. Lee TW, Southern KW Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst Rev 2012, 10. CD005599.
13. Corbyn Z Promising new era dawns for cystic fibrosis treatment. Lancet 2012, 379:1475-1476.
14. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008, 105:2064-2069.
15. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
16. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
17. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011, 38:59-69.
18. Konstan M, Accurso F, De Boeck K, et al. Targeting class 1 mutations: update on ataluren as a promising treatment for nonsense mutation in CF. Pediatr Pulmonol 2012, S35:108-109.
19. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009, 106:18825-18830.
20. Davies JCLH, Yen K, Ahrens R Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation. J Cyst Fibros 2012, 11:S13. on behalf of the VX-08-770-103 study group, (abstr).
21. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012, 11:237-245.
22. Van Goor FYH, Burton B, Huang CJ, Hoffman BJ Ivacaftor potentiates mutant CFTR forms associated with residual function. J Cyst Fibros 2012, 11:S31. (abstr).
23. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012, 142:718-724.
24. Van Goor F, Straley KS, Cao D, et al. Rescue of deltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1117-L1130.
25. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011, 108:18843-18848.
26. Boyle MP, Bell S, Konstan M, et al. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508del homozygous patients: phase II study results. Pediatr Pulmonol 2012, 47(suppl 35):315. (abstr).
27. Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 2012, 148:164-174.
28. Lilley M, Christian S, Hume S, et al. Newborn screening for cystic fibrosis in Alberta: two years of experience. Paediatr Child Health 2010, 15:590-594.
29. Thauvin-Robinet C, Munck A, Huet F, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009, 46:752-758.
30. Ashlock MA, Olson ER Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease. Annu Rev Med 2011, 62:107-125.
31. De Boeck K, Bulteel V, Tiddens H, et al. Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). J Cyst Fibros 2011, 10:S67-S74.
32. Viviani L, Zolin A, Olseson HV, et al. European Cystic Fibrosis Patient Registry Annual Report 2008-2009 2012, European Cystic Fibrosis Society, Karup, Denmark.
33. Noone PG, Pue CA, Zhou Z, et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 2000, 162:1919-1924.
34. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics 2006, 118:1260-1265.
35. Cai ZW, Liu J, Li HY, Sheppard DN Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis. Acta Pharmacol Sin 2011, 32:693-701.